SPAPB1A10.13 Antibody

What is SPAPB1A10.13 and what research applications is the antibody suitable for?

SPAPB1A10.13 is a gene/protein from Schizosaccharomyces pombe (fission yeast), following the systematic naming convention for S. pombe genes. The antibody against this protein is primarily used in fundamental research applications including Western blotting, immunoprecipitation, and potentially immunofluorescence studies of fission yeast cellular processes .

The antibody is available in purified form (typically 10mg) and can be applied in various experimental contexts where detection of the native protein in yeast extracts or recombinant expressed protein is required. Researchers should validate the antibody for specific applications as performance may vary across different experimental conditions.

What validation methods should I use to confirm SPAPB1A10.13 Antibody specificity?

Validation of SPAPB1A10.13 Antibody specificity requires a multi-method approach:

• Western Blot Analysis: Run wild-type S. pombe extracts alongside SPAPB1A10.13 deletion mutants. A specific antibody will detect bands of the predicted molecular weight in wild-type samples but not in deletion mutants.

• Recombinant Protein Controls: Express tagged SPAPB1A10.13 protein (His-tag or GST-tag) and confirm detection with both the antibody and an anti-tag antibody.

• Immunoprecipitation followed by Mass Spectrometry: Confirm that the immunoprecipitated protein is indeed SPAPB1A10.13.

• Pre-absorption Tests: Pre-incubate the antibody with recombinant SPAPB1A10.13 protein before immunostaining to confirm signal reduction.

• Cross-reactivity Assessment: Test against related proteins to ensure the antibody does not cross-react with other S. pombe proteins.

For meaningful results, implement at least two different validation methods appropriate to your experimental context.

What are the optimal conditions for Western blotting with SPAPB1A10.13 Antibody?

For optimal Western blot results with SPAPB1A10.13 Antibody, follow these protocol recommendations:

Secondary antibody options include goat anti-rabbit IgG conjugated with biotin, FITC, or HRP, with HRP conjugates particularly suitable for Western blotting applications . Always perform a titration experiment with different antibody concentrations to determine optimal signal-to-noise ratio.

How should I troubleshoot non-specific binding when using SPAPB1A10.13 Antibody in immunofluorescence studies?

When encountering non-specific binding in immunofluorescence experiments with SPAPB1A10.13 Antibody:

• Increase Blocking Stringency:

  • Extend blocking time to 2 hours

  • Use 3-5% BSA with 0.1% Triton X-100

  • Add 5-10% normal serum from the species of the secondary antibody

• Optimize Antibody Concentration:

  • Perform a dilution series (typically starting from 1:100 to 1:1000)

  • Include proper negative controls (secondary antibody only; primary antibody pre-absorbed with antigen)

• Modify Fixation Method:

  • Compare methanol, formaldehyde, and glutaraldehyde fixation

  • For S. pombe, 4% paraformaldehyde for 15 minutes often preserves antigenic epitopes

• Implement Additional Washing Steps:

  • Increase wash duration and frequency

  • Add 0.05-0.1% Tween-20 to wash buffers

• Pre-absorption Strategy:

  • Pre-incubate the antibody with non-specific proteins (e.g., cell lysate from SPAPB1A10.13 deletion strain)

  • Use diluted antibody for staining after removing precipitates

For best results, document all optimization steps systematically in your laboratory notebook to establish a reproducible protocol.

How can SPAPB1A10.13 Antibody be used in ChIP-seq experiments to study protein-DNA interactions?

SPAPB1A10.13 Antibody can be effectively implemented in Chromatin Immunoprecipitation followed by sequencing (ChIP-seq) experiments through the following specialized protocol:

• Crosslinking Optimization:

  • For S. pombe, use 1% formaldehyde for 15 minutes at room temperature

  • Quench with 125mM glycine for 5 minutes

• Chromatin Fragmentation:

  • Sonicate to achieve fragment sizes of 200-500bp

  • Verify fragmentation efficiency by agarose gel electrophoresis

• Immunoprecipitation Parameters:

  • Use 2-5μg antibody per 25-50μg chromatin

  • Pre-clear chromatin with protein A/G beads

  • Include input controls, IgG controls, and ideally a positive control antibody against a known DNA-binding protein

• Washing and Elution:

  • Implement stringent washing with increasing salt concentrations

  • Elute at 65°C with frequent agitation

• Library Preparation Considerations:

  • Perform sequencing adapter ligation after DNA purification

  • Use spike-in controls for normalization

• Data Analysis Pipeline:

  • Align reads to S. pombe genome

  • Call peaks using MACS2 or similar algorithms

  • Annotate peaks relative to genomic features

This approach enables genome-wide identification of SPAPB1A10.13 binding sites, providing insights into potential regulatory functions of this protein in S. pombe.

What strategies can be employed to improve immunoprecipitation efficiency with SPAPB1A10.13 Antibody?

Improving immunoprecipitation (IP) efficiency with SPAPB1A10.13 Antibody requires optimization of multiple parameters:

• Lysis Buffer Composition:

  • Test different detergent combinations (NP-40, Triton X-100, CHAPS)

  • Include salt concentrations between 100-250mM NaCl

  • Supplement with protease/phosphatase inhibitors and reducing agents

• Antibody Coupling Methods:

  • Direct coupling to beads (covalent attachment via crosslinking)

  • Pre-formation of antibody-antigen complexes prior to bead addition

  • Comparison of protein A vs. protein G beads for rabbit IgG capture

• Incubation Conditions:

  • Optimize antibody-to-lysate ratio (typically 1-5μg antibody per 500μg protein)

  • Compare incubation times (4 hours vs. overnight) and temperatures (4°C vs. room temperature)

• Bead Selection and Preparation:

  • Pre-clear lysates with beads to reduce non-specific binding

  • Block beads with BSA or non-relevant proteins before adding antibody

• Washing Protocol Optimization:

  • Develop gradient washing with incrementally increasing stringency

  • Include detergent in early washes, reduce in later washes

For particularly challenging IPs, consider dual-epitope approaches by tagging SPAPB1A10.13 with an affinity tag and performing tandem purification with both the antibody and anti-tag antibodies.

Does SPAPB1A10.13 Antibody cross-react with homologous proteins in other model organisms?

Cross-reactivity analysis of SPAPB1A10.13 Antibody reveals significant considerations for researchers working across different model systems:

When considering cross-species applications, sequence alignment analysis should be performed to identify conserved epitopes. If cross-reactivity is observed, it may be exploited for comparative studies but must be thoroughly validated using knockout/knockdown controls in each organism. For definitive results when studying homologs in other species, species-specific antibodies remain preferable.

How can I quantitatively compare the performance of different SPAPB1A10.13 Antibody lots or sources?

To ensure experimental reproducibility when changing antibody lots or sources, implement this quantitative comparison framework:

• Sensitivity Assessment:

  • Perform limiting dilution analysis with known concentrations of recombinant protein

  • Calculate limit of detection (LOD) for each antibody lot

  • Generate standard curves to determine linear detection range

• Specificity Evaluation:

  • Western blot analysis with both wild-type and SPAPB1A10.13 deletion strains

  • Calculate signal-to-noise ratio using densitometry

  • Document all non-specific bands and their molecular weights

• Reproducibility Testing:

  • Perform triplicate experiments under identical conditions

  • Calculate coefficient of variation (CV%) for signal intensity

  • Test across multiple independent sample preparations

• Comparative Immunoprecipitation Efficiency:

  • Measure percentage of target protein depleted from input

  • Compare co-immunoprecipitation of known interacting partners

  • Analyze by mass spectrometry to identify differences in binding partners

• Statistical Validation:

  • Apply appropriate statistical tests (t-tests or ANOVA) to determine if differences between lots are significant

  • Establish acceptance criteria before testing (e.g., <15% variation in key parameters)

Document all findings in a formal antibody validation report to maintain laboratory quality control standards and ensure experimental reproducibility over time.

What are the optimal storage conditions for maintaining SPAPB1A10.13 Antibody activity long-term?

Long-term preservation of SPAPB1A10.13 Antibody activity requires careful attention to storage conditions:

• Temperature Considerations:

  • Store stock antibody at -20°C for long-term storage (up to 1 year)

  • Working aliquots can be maintained at 4°C for up to 1 month

  • Avoid repeated freeze-thaw cycles (limit to <5 cycles)

• Aliquoting Strategy:

  • Prepare multiple small-volume aliquots (10-20μL) immediately upon receipt

  • Use sterile microcentrifuge tubes with secure seals

  • Mark each tube with date, concentration, and lot number

• Buffer Composition:

  • Maintain in phosphate-buffered saline (PBS) with 0.09% sodium azide as preservative

  • For extended stability, consider adding stabilizing proteins (BSA, 1-5%)

  • Glycerol (30-50%) can be added for cryoprotection

• Handling Practices:

  • Always use sterile technique when accessing antibody stocks

  • Allow refrigerated antibodies to equilibrate to room temperature before opening

  • Centrifuge briefly before opening to collect solution at the bottom of the tube

• Stability Monitoring:

  • Periodically test activity using consistent positive controls

  • Document any changes in required working concentration over time

  • Consider preparing reference standards from initial lot for comparison

Under optimal storage conditions, antibody activity can be maintained for at least 12 months from the date of receipt . Any loss of activity over time may require adjustment of working dilutions for consistent experimental results.

How can I resolve inconsistent results when using SPAPB1A10.13 Antibody across different experimental batches?

Addressing batch-to-batch variation requires systematic troubleshooting of experimental variables:

• Sample Preparation Assessment:

  • Standardize cell growth conditions (media composition, harvest timing)

  • Implement consistent lysis protocols with validated protease inhibitor cocktails

  • Measure and normalize protein concentration using multiple methods (BCA, Bradford)

• Antibody Validation Checks:

  • Compare antibody lot numbers and request Certificate of Analysis from supplier

  • Test working dilutions of new antibody lots against standards

  • Consider creating an internal reference standard from a well-characterized sample

• Protocol Standardization:

  • Document detailed protocols with exact buffer compositions

  • Maintain consistent incubation times and temperatures

  • Use automated systems where possible to reduce operator variability

• Technical Controls Implementation:

  • Include loading controls for Western blots (e.g., total protein stain)

  • Utilize positive and negative controls in every experiment

  • Implement spike-in standards for quantitative applications

• Environmental Factor Analysis:

  • Log laboratory temperature and humidity conditions

  • Ensure consistent reagent quality by testing critical components

  • Consider seasonal variations that might affect equipment performance

• Statistical Approach to Variability:

  • Perform power analysis to determine appropriate sample size

  • Apply robust statistical methods designed for handling batch effects

  • Consider technical replicates across multiple days for critical experiments

When systematic troubleshooting fails to resolve inconsistencies, consider alternative detection methods or antibodies targeting different epitopes of SPAPB1A10.13.

How can SPAPB1A10.13 Antibody be adapted for super-resolution microscopy techniques?

Optimizing SPAPB1A10.13 Antibody for super-resolution microscopy requires specialized adaptations:

• Direct Fluorophore Conjugation:

  • Consider custom conjugation with bright, photostable fluorophores (Alexa Fluor 647, Atto 488)

  • Optimize degree of labeling (DOL) to avoid over-labeling which can cause quenching

  • Validate that conjugation doesn't impair antibody binding using parallel Western blot experiments

• Sample Preparation Refinements:

  • Use thinner coverslips (No. 1.5H, 170 ± 5 μm) for optimal optical properties

  • Implement clearing techniques to reduce background autofluorescence

  • For STORM/PALM: ensure appropriate buffer conditions with oxygen scavenging systems

• Technique-Specific Considerations:

  • For STED: Use fluorophores with appropriate stimulated emission profiles

  • For STORM/PALM: Optimize switching buffer composition for blinking behavior

  • For SIM: Ensure high signal-to-noise ratio and sample stability

• Control Experiments:

  • Perform rigorous specificity controls using SPAPB1A10.13 deletion strains

  • Include fiducial markers for drift correction during long acquisitions

  • Validate resolution improvement using known structures as internal references

• Post-acquisition Analysis:

  • Apply appropriate reconstruction algorithms specific to each technique

  • Implement cluster analysis to characterize SPAPB1A10.13 distribution patterns

  • Consider quantitative approaches to measure localization precision

These adaptations enable visualization of SPAPB1A10.13 subcellular localization with nanometer-scale precision, potentially revealing previously undetectable patterns of protein organization within S. pombe cells.

What approaches can be used to resolve conflicting data between antibody-based detection of SPAPB1A10.13 and genetic expression data?

When faced with discrepancies between antibody-based protein detection and genetic expression data for SPAPB1A10.13:

• Multi-level Validation Strategy:

  • Compare protein abundance (Western blot/IP) with mRNA levels (qRT-PCR/RNA-seq)

  • Implement alternative detection methods (e.g., epitope tagging, mass spectrometry)

  • Examine protein half-life using cycloheximide chase experiments

• Regulatory Mechanism Investigation:

  • Assess post-transcriptional regulation through RNA-binding protein analysis

  • Examine post-translational modifications that might affect antibody recognition

  • Investigate protein degradation pathways (proteasome, autophagy)

• Technical Consideration Analysis:

  • Evaluate antibody epitope accessibility under different experimental conditions

  • Assess specificity controls across all experimental systems

  • Review normalization methods for both protein and RNA quantification

• Temporal Resolution Examination:

  • Perform time-course experiments to detect potential delays between transcription and translation

  • Implement pulse-chase labeling to track protein synthesis and turnover

  • Consider cell cycle effects on gene expression versus protein abundance

• Conditional Factor Evaluation:

  • Test different environmental conditions that might affect either transcription or translation

  • Examine stress responses that could selectively impact protein or mRNA stability

  • Consider cell-to-cell variability using single-cell approaches

When properly investigated, such discrepancies often reveal interesting biological insights about gene regulation rather than technical artifacts, potentially leading to discovery of novel regulatory mechanisms affecting SPAPB1A10.13 expression and function.